

# **Cell Therapy**

## **Part I: Technologies, Ethics & Regulations**

**by**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**September 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 470 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the 2017 version is included in a special report on gene therapy published by Jain PharmaBiotech. Other reports written by Prof. Jain have been published by PJB Publications, D & MD, Reuter's Business Insight, and Decision Resources Inc. Cell Therapy is one of the several in-house publications of Jain PharmaBiotech.

Prof. Jain's recent books include "Handbook of Nanomedicine" (1<sup>st</sup> ed by Springer 2008, Chinese ed by Peking University Press 2011, 2<sup>nd</sup> edition 2012, 3<sup>rd</sup> ed 2017 by Springer), "Textbook of Personalized Medicine" (1<sup>st</sup> ed by Springer 2009; Japanese edition 2012; 2<sup>nd</sup> ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016; 2<sup>nd</sup> edn Springer 2017), Handbook of Neuroprotection (Springer 2011), Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

**September 2017 (first edition published July 2001)  
Copyright © 2017 by**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax:     +4161-6924461  
Email:         info@pharmabiotech.ch  
Web site:      http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>27</b>
<b>1. Introduction to Cell Therapy .....</b>	<b>31</b>
<b>Introduction .....</b>	<b>31</b>
<b>Historical landmarks of cell therapy .....</b>	<b>31</b>
<b>Interrelationship of cell therapy technologies .....</b>	<b>33</b>
<b>Cells and organ transplantation .....</b>	<b>34</b>
<b>Cells and protein/gene therapy .....</b>	<b>34</b>
<b>Cell therapy and regenerative medicine.....</b>	<b>35</b>
<b>Cell therapy and tissue engineering.....</b>	<b>36</b>
<b>Therapy based on cells involved in disease.....</b>	<b>36</b>
<b>Advantages of therapeutic use of cells .....</b>	<b>37</b>
<b>Synthetic cell therapy .....</b>	<b>37</b>
<b>Cell-based drug delivery .....</b>	<b>38</b>
<i>Cells as vehicles for gene delivery .....</i>	<i>38</i>
<i>Red blood cells as vehicles for drug delivery.....</i>	<i>38</i>
<i>Advantages of cell-based drug delivery.....</i>	<i>40</i>
<i>Limitations of cell-based drug delivery.....</i>	<i>40</i>
<b>2. Cell Therapy Technologies .....</b>	<b>41</b>
<b>Introduction .....</b>	<b>41</b>
<b>Cell types used for therapy .....</b>	<b>41</b>
<b>Sources of cells.....</b>	<b>41</b>
Bone marrow.....	42
Blood component therapy .....	42
<i>Therapeutic apheresis.....</i>	<i>42</i>
<i>Leukoreduction .....</i>	<i>43</i>
<i>Platelet therapy .....</i>	<i>43</i>
Cell lines.....	44
<i>Immortalized cells.....</i>	<i>44</i>
Xenografts .....	44
<b>Basic technologies for cell therapy .....</b>	<b>44</b>
Cell culture .....	44
<i>Automated cell culture devices .....</i>	<i>45</i>
<i>Cell culture for adoptive cell therapy .....</i>	<i>45</i>
<i>Observation of stem cell growth and viability.....</i>	<i>45</i>
<i>OpTmizer™ CTS™ T cell expansion tissue culture medium .....</i>	<i>45</i>
<i>Companies involved in cell culture.....</i>	<i>46</i>
Cell sorting .....	47
<i>Flow cytometry.....</i>	<i>48</i>
<i>Applications of flow cytometry .....</i>	<i>49</i>
<i>A dielectrophoretic system for cell separation .....</i>	<i>49</i>
<i>Adult stem cell sorting by identification of surface markers .....</i>	<i>49</i>
<i>ALDESORTER system for isolation of stem cells.....</i>	<i>50</i>
<i>Dynabead technology for cell sorting .....</i>	<i>50</i>
<i>Elutra® Cell Separation System.....</i>	<i>50</i>
<i>Magnetophoretic array-based cell sorting for further studies.....</i>	<i>50</i>
<i>Molecular beacons for specific detection and isolation of stem cells .....</i>	<i>51</i>
<i>Multitarget magnetic activated cell sorter.....</i>	<i>51</i>
<i>Nanocytometry .....</i>	<i>51</i>
<i>Scepter™ cytometer.....</i>	<i>52</i>
<i>Companies supplying cell sorters .....</i>	<i>52</i>
Cell analysis .....	53
<i>Cell analyzers.....</i>	<i>53</i>
<i>In vivo cell imaging .....</i>	<i>53</i>
<i>Measuring cell density .....</i>	<i>54</i>
Single-cell gene expression analysis .....	54
<i>Fluorescent in situ RNA sequencing .....</i>	<i>56</i>
<i>Single-cell RNA sequencing of stem cells.....</i>	<i>56</i>
Preservation of cells .....	56
<i>Innovations in cryopreservation .....</i>	<i>57</i>
Packaging of cells .....	58
Selective expansion of T cells for immunotherapy .....	58
Cloning and cell therapy .....	59
Techniques for cell manipulation .....	59
Altering function of adult human cells .....	60
<b>Cell-based drug discovery.....</b>	<b>60</b>

Advantages and limitations of cell-based assays for drug discovery .....	60
<i>Advantages and limitations of cell-based toxicity screening</i> .....	61
<i>Quality control of cells for drug discovery</i> .....	61
Companies involved in cell-based drug discovery .....	61
<b>Introduction of foreign materials into cells to develop therapeutics</b> .....	<b>63</b>
Use of cell-penetrating peptides for intracellular transduction .....	63
<b>Drug delivery systems for cell therapy</b> .....	<b>64</b>
Intravenous delivery of stem cells .....	64
Intraarterial delivery of stem cells .....	64
Pharmacologically active microcarriers .....	64
Targeted delivery of engineered cells to specific tissues via circulation .....	65
Devices for delivery of cell therapy .....	65
<b>Artificial cells</b> .....	<b>66</b>
Applications of artificial cells .....	66
<b>Cell encapsulation</b> .....	<b>67</b>
Cell-in-a-Box® .....	67
Diffusion capsule for cells .....	68
Encapsulated cell biodelivery .....	68
Therapeutic applications of encapsulated cells .....	68
Nitric oxide delivery by encapsulated cells .....	70
Implantation of microencapsulated genetically modified cells .....	70
Ferrofluid microcapsules for tracking with MRI .....	71
Companies involved in encapsulated cell technology .....	71
<b>Electroporation</b> .....	<b>71</b>
<b>Gene therapy</b> .....	<b>72</b>
Cell-mediated gene therapy .....	72
<i>Fibroblasts</i> .....	73
<i>Chondrocyte</i> .....	73
<i>Skeletal muscle cells</i> .....	74
<i>Vascular smooth muscle cells</i> .....	74
<i>Keratinocytes</i> .....	74
<i>Hepatocytes</i> .....	75
<i>Lymphocytes</i> .....	75
Cell-based CRISPR delivery .....	75
<b>In vivo tracking of cells</b> .....	<b>76</b>
Molecular imaging for tracking cells .....	76
<i>MRI technologies for tracking cells</i> .....	77
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i> .....	78
<i>Survival of labeled hMSCs in regenerative therapy grafts</i> .....	78
<i>Visualization of gene expression in vivo by MRI</i> .....	78
Optogenetic monitoring of cell therapies .....	79
<b>Role of nanobiotechnology in development of cell therapy</b> .....	<b>79</b>
Nano-biocomposites containing living cells .....	80
<b>Cell transplantation for development of organs</b> .....	<b>80</b>
<b>Cells transplantation and tolerance</b> .....	<b>80</b>
Strategies to improve tolerance of transplanted cells .....	81
<i>Encapsulation to prevent immune rejection</i> .....	81
<i>Expansion of allospecific regulatory T cells</i> .....	81
<i>Prevention of rejection of xenotransplants</i> .....	82
<b>Removal and replacement of pathogenic cells of the body</b> .....	<b>82</b>
Therapeutic leukocytapheresis .....	82

<b>3. Stem Cells</b> .....	<b>83</b>
<b>Introduction</b> .....	<b>83</b>
<b>Biology of stem cells</b> .....	<b>83</b>
Embryonic stem cells .....	84
Growth and differentiation of ESCs .....	84
Mechanisms of differentiation of ESCs .....	85
<i>Chemical regulation of stem cell differentiation</i> .....	85
<i>In vitro differentiation of hESCs</i> .....	85
<i>SIRT1 regulation during stem cell differentiation</i> .....	86
Regulation of stem cell self-renewal and differentiation .....	86
<i>hESCs for reprogramming human somatic nuclei</i> .....	86
<i>Stem cells differentiation in the pituitary gland</i> .....	87
Influence of microenvironment on ESCs .....	87
Role of genes in differentiation of ESCs .....	87
<i>Global transcription in pluripotent ESCs</i> .....	87
<i>Role of p53 tumor suppressor gene in stem cell differentiation</i> .....	88
<i>Role of Pax3 gene in stem cell differentiation</i> .....	88
<i>Signaling pathways and ESC genes</i> .....	88
Epigenetics of hESCs .....	89

<i>Chromatin as gene regulator for ESC development</i> .....	90
Mechanism of regulation of stem cells for regeneration of body tissues.....	90
<i>Role of microenvironments in the regulation of stem cells</i> .....	90
<i>Regulation and regeneration of intestinal stem cells</i> .....	91
Parthenogenesis and human stem cells.....	91
<i>Uniparental ESCs</i> .....	92
<i>Haploid ESCs</i> .....	92
Bone marrow stem cells.....	93
Hematopoietic stem cells.....	93
<i>Clonal events that regulate HSC development</i> .....	95
<i>Derivation of HSCs from ESCs</i> .....	95
<i>Role of HSCs in the immune system</i> .....	95
Mesenchymal stem cells.....	96
<i>Cryopreservation of MSCs</i> .....	97
Multipotent adult progenitor cells.....	98
Side population stem cells.....	98
Differentiation of adult stem cells.....	99
Growth and differentiation of HSCs.....	100
<i>HSCs and aging</i> .....	100
<i>Mathematical modeling of differentiation of HSCs</i> .....	100
<i>Role of prions in self renewal of HSCs</i> .....	101
<i>Signaling pathways in the growth and differentiation of HSCs</i> .....	101
<b>Sources of stem cells</b> .....	<b>101</b>
Sources of human embryonic stem cells.....	101
Nuclear transfer to obtain hESCs.....	102
Direct derivation of hESCs from embryos without nuclear transfer.....	103
Alternative methods of obtaining hESCs.....	103
<i>Establishing hESC lines without destruction of embryo</i> .....	103
<i>Altered nuclear transfer</i> .....	104
Advantages and disadvantages of ESCs for transplantation.....	105
Use of ESC cultures as an alternative source of tissue for transplantation.....	105
Spermatogonial stem cells.....	106
Very small embryonic-like stem cells.....	107
Amniotic fluid as a source of stem cells.....	107
<i>Amniotic fluid stem cells for tissue repair and regeneration</i> .....	107
<i>Generation of iPS cells from AF cells</i> .....	108
Placenta as source of stem cells.....	108
<i>Amnion-derived multipotent progenitor cells</i> .....	108
<i>Placenta as a source of HSCs</i> .....	109
<i>Umbilical cord as a source of MSCs</i> .....	109
Umbilical cord blood as source of neonatal stem cells.....	110
<i>Cryopreservation of UCB stem cells</i> .....	111
<i>Epigenetic programming for expansion of UCB cells</i> .....	111
<i>UCB as source of MSCs</i> .....	111
<i>Applications of UCB</i> .....	112
<i>Advantages of UCB</i> .....	112
<i>Limitations of the use of UCB and measures to address them</i> .....	113
<i>Licensing and patent disputes involving UCB</i> .....	114
<i>Infections following UCB transplants</i> .....	114
<i>Unanswered questions about UCB transplantation</i> .....	115
<i>Companies involved in UCB banking</i> .....	115
<i>UCB banking in the UK</i> .....	117
<i>US national UCB banking system</i> .....	117
<i>Future prospects of UCB</i> .....	118
<b>Techniques of nuclear reprogramming for stem cells</b> .....	<b>119</b>
<b>Induced pluripotent stem cells derived from human somatic cells</b> .....	<b>119</b>
Characteristics of iPSCs.....	119
DNA methylation patterns of iPSCs.....	120
Techniques for obtaining iPSCs.....	120
iPSCs derived from skin.....	120
iPSCs derived through somatic cell nuclear transfer (SCNT).....	121
<i>iPSCs derived from oocytes</i> .....	121
<i>iPSCs derived from adult stem cells using SCNT</i> .....	121
iPSCs derived from blood.....	121
Use of retroviral vectors for generation of iPSCs.....	122
Use of non-integrating viral vectors for generation of iPSCs.....	122
Generation of other cells from iPSCs.....	123
<i>Generation of HSCs from iPSCs</i> .....	123
<i>Generation of MSCs from iPSCs</i> .....	123
<i>Generation of RBCs from iPSCs</i> .....	124
Banks providing patient-specific iPSC lines.....	124

Center for iPS Cell Research Application.....	124
Companies providing iPSCs .....	125
Generation of clinically relevant iPSCs .....	125
<i>Equivalence of human iPSCs and ESCs.....</i>	126
<i>Genome editing and iPSCs .....</i>	126
<i>iPSCs and disease modeling .....</i>	127
<i>iPSCs for patient-specific regenerative medicine .....</i>	127
<i>Concluding remarks about clinical potential of iPSCs.....</i>	128
<b>Induced conditional self-renewing progenitor cells .....</b>	<b>129</b>
<b>iXEN cells.....</b>	<b>129</b>
<b>Epiblast stem cells .....</b>	<b>129</b>
Comparison of development of human and mouse ESCs .....	129
Conversion of hESCs to mouse ESC-like naïve states.....	130
<b>Sources of adult human stem cells .....</b>	<b>130</b>
Adipose tissue as a source of stem cells.....	131
<i>Encapsulation and hypothermic storage of adipose-derived stem cells .....</i>	131
<i>Intravenous infusion of adipose tissue derived MSCs .....</i>	132
<i>iPSCs derived from adult human adipose stem cells .....</i>	132
<i>Regulation of adipose stem cells differentiation.....</i>	132
<i>Transforming adult adipose stem cells into other cells .....</i>	132
Endometrium as a source of adult stem cells .....	133
Multipotent stem-like cells derived from vascular endothelial cells.....	133
Skin as a source of stem cells.....	133
<i>Controlling the maturation of embryonic skin stem cells.....</i>	133
<i>Epidermal neural crest stem cells.....</i>	134
<i>Follicle stem cells.....</i>	134
<i>Mesenchymal stem cells in skin .....</i>	135
<i>Regulation of stem cells in hair follicles.....</i>	135
<i>Skin-derived precursor cells .....</i>	135
Regulation of epidermal stem cells by circadian rhythms.....	136
Stem cells in teeth .....	136
Peripheral blood stem cells.....	137
Spleen as a source of adult stem cells .....	137
Search for master stem cells .....	137
Vascular cell platform to self-renew adult HSC.....	138
<b>Adult stem cells vs embryonic stem cells .....</b>	<b>138</b>
Biological differences between adult and embryonic stem cells .....	138
Neural crest stem cells from adult hair follicles .....	139
Transdifferentiation potential of adult stem cells .....	139
Attempts at stimulus-triggered acquisition of pluripotency .....	140
Limitations of adult stem cells .....	141
Pitfalls of pluripotency .....	141
<b>Comparison of human stem cells according to derivation .....</b>	<b>142</b>
<b>VENT cells.....</b>	<b>142</b>
<b>ESC banking.....</b>	<b>142</b>
<b>Stem cell technologies .....</b>	<b>143</b>
Analysis of stem cell growth and differentiation .....	143
Activation of bone marrow stem cells into therapeutic cells .....	143
Role of nitric oxide in stem cell mobilization and differentiation.....	143
Role of natriuretic peptide receptor-C in self-renewal of murine ESCs .....	144
Stem cell biomarkers.....	144
<i>Endoglin as a functional biomarker of HSCs.....</i>	144
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs .....</i>	145
<i>SSEA-4 as biomarker of MSCs .....</i>	145
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells .....</i>	145
<i>Neural stem cell biomarker .....</i>	145
<i>Protein expression profile as biomarker of stem cells.....</i>	146
<i>Real-time PCR for quantification of protein biomarkers .....</i>	146
Study of stem cell pathways.....	146
Stem cell genomics .....	147
<i>Gene expression in hESCs.....</i>	147
<i>Genomic alterations in cultured hESCs.....</i>	147
<i>Study of transcriptional regulation of stem cell genes .....</i>	148
<i>Casanova gene in zebrafish.....</i>	148
<i>Nanog gene.....</i>	148
Gene inactivation to study hESCs.....	149
<i>RNAi to study gene inactivation in hESCs.....</i>	150
<i>Study of ESC development by inducible RNAi.....</i>	150
<i>Targeting Induced Local Lesions in Genomes.....</i>	151
<i>Homologous recombination of ESCs.....</i>	151
Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease.....	151

miRNA and stem cells .....	152
<i>Role of miRNAs in gene regulation during stem cell differentiation</i> .....	152
<i>Influence of miRNA on stem cell formation and maintenance</i> .....	152
<i>Transcriptional regulators of ESCs control miRNA gene expression</i> .....	153
Stem cells and cloning .....	153
<i>Cell nuclear replacement and cloning</i> .....	153
<i>Nuclear transfer and ESCs</i> .....	154
<i>Cloning from differentiated cells</i> .....	155
<i>Cloning mice from adult stem cells</i> .....	155
<i>Creating interspecies stem cells</i> .....	156
<i>Cloned cells for transplantation medicine</i> .....	156
<i>Claims of cloning of hESCs</i> .....	157
<i>hESCs derived by SCNT</i> .....	158
Cytogenetics of embryonic stem cells .....	159
Stem cell proteomics .....	159
<i>Comparative proteomic analysis of somatic cells, iPSCs and ESCs</i> .....	160
<i>hESC phosphoproteome</i> .....	160
<i>Proteomic studies of mesenchymal stem cells</i> .....	161
<i>Proteomic profiling of neural stem cells</i> .....	161
<i>Proteome Biology of Stem Cells Initiative</i> .....	161
Technologies for mobilization, expansion, and engraftment of stem cells .....	162
<i>Chemoattraction of neuronal stem cells through GABA receptor</i> .....	162
<i>Enhancement of HSC engraftment by calcium-sensing receptor</i> .....	163
<i>Ex vivo expansion of human HSCs in culture</i> .....	163
<i>Ex vivo expansion of MSCs</i> .....	164
<i>Ex vivo expansion of UCB cells for transplantation</i> .....	164
<i>Expansion of adult stem cells by activation of Oct4</i> .....	164
<i>Expansion of transduced HSCs in vivo</i> .....	164
<i>Expansion of stem cells in vivo by Notch receptor ligands</i> .....	165
<i>In vivo adipogenesis induced by adipose tissue-derived stem cells</i> .....	165
<i>Selective mobilization of progenitor cells from bone marrow</i> .....	165
<i>Selective Amplification</i> .....	166
<i>Synthetic substrates for ESC growth and expansion</i> .....	166
Technologies for inducing differentiation of stem cells .....	166
<i>Enhancement of stem cell differentiation by Homspera</i> .....	166
<i>Generation of RBCs from HSCs</i> .....	167
<i>Generation of multiple types of WBCs from hESCs and iPSCs</i> .....	167
<i>Growth factor-induced differentiation of MAPCs</i> .....	167
<i>Lineage selection to induce differentiation of hESCs</i> .....	168
<i>Mechanical strain to induce MSC differentiation</i> .....	168
<i>Neurotrophin-mediated survival and differentiation of hESCs</i> .....	168
<i>Synthetic biology and stem cells</i> .....	169
<i>Use of RNAi to expand the plasticity of autologous adult stem cells</i> .....	169
<i>Use of various molecules to induce differentiation of stem cells</i> .....	170
Limitations of the currently available stem cell lines in the US .....	170
Stem cell separation .....	170
Stem cell culture .....	171
<i>Culture of hMSCs</i> .....	172
<i>Elimination of contaminating material in stem cell culture</i> .....	172
<i>Long-term maintenance of MSC multipotency in culture</i> .....	173
<i>Nanofiber scaffolds for stem cell culture</i> .....	174
Conversion of stem cells to functioning adipocytes .....	174
Mass production of ESCs .....	174
Promoting survival of dissociated hESCs .....	175
Analysis and characterization of stem cells .....	175
Harvesting and identification of EPCs .....	176
Labeling of stem cells .....	176
Labeling, imaging and tracking of stem cells in vivo .....	177
<i>Perfluorocarbon nanoparticles to track therapeutic cells in vivo</i> .....	177
<i>PET imaging for tracking of stem cells</i> .....	177
<i>Project for imaging in stem cell therapy research</i> .....	177
<i>Quantum dots for labeling and imaging of stem cells</i> .....	178
<i>Radiolabeling of MSCs for in vivo tracking</i> .....	178
<i>Superparamagnetic iron oxide nanoparticles for tracking MSCs</i> .....	178
<i>Tracking of transplanted muscle stem cells</i> .....	179
<b>Applications of stem cells .....</b>	<b>179</b>
Commercial development and applications of adult stem cells .....	180
<i>Preparation of cells for therapeutic administration to patients</i> .....	180
<i>Retrodifferentiation of stem cells</i> .....	180
<i>MultiStem</i> .....	180
Controlling the maintenance process of hematopoietic stem cells .....	181

<i>Self renewal and proliferation of HSCs</i> .....	181
<i>Aging and rejuvenation of HSCs</i> .....	181
<i>Aging and MSCs</i> .....	182
iPSC-based modeling of late-onset age-related diseases .....	182
Peripheral blood stem cell transplantation .....	182
Role of stem cells in regeneration .....	183
<i>Pluripotent stem-cell-derived gastric organoids</i> .....	183
<i>Promotion of regeneration by Wnt/beta-catenin signaling</i> .....	183
<i>Stem cell activation for regeneration by using glucocorticoids</i> .....	184
Stem cells and human reproduction .....	184
<i>Expansion of spermatogonial stem cells</i> .....	184
<i>Conversion of ESCs into spermatogonial stem cells</i> .....	184
<i>Conversion of stem cells to oocytes</i> .....	185
<i>ESCs for treatment of infertility in women</i> .....	185
<i>Cloning human embryos from oocytes matured in the laboratory</i> .....	186
<i>In utero stem cell transplantation</i> .....	186
Innovations in delivery of stem cells.....	187
<i>Polymeric capsules for stem cell delivery</i> .....	188
Immunological aspects of hESC transplantation .....	188
<i>Immunosuppression to prevent rejection of hESC transplants</i> .....	188
<i>Histocompatibility of hESCs</i> .....	189
<i>Strategies for promoting immune tolerance of hESCs</i> .....	189
Stem cells for organ vascularization .....	190
<i>Activation of EphB4 to enhance angiogenesis by EPCs</i> .....	190
Advantages and limitations of clinical applications of iPSCs .....	191
Advantages and limitations of clinical applications of MSCs.....	191
Biofusion by genetically engineering stem cells .....	191
Stem cell gene therapy .....	192
<i>Combination of gene therapy with nuclear transfer</i> .....	192
<i>Gene delivery to stem cells by artificial chromosome expression</i> .....	192
<i>Genetic manipulation of ESCs</i> .....	193
<i>Genetic engineering of human stem cells for enhancing angiogenesis</i> .....	193
<i>HSCs for gene therapy</i> .....	193
<i>iPSCs for targeted gene correction of <math>\alpha</math>1-antitrypsin deficiency</i> .....	194
<i>Helper-dependent adenoviral vectors for gene transfer in ESCs</i> .....	194
<i>Lentiviral vectors for in vivo gene transfer to stem cells</i> .....	195
<i>Linker based sperm-mediated gene transfer technology</i> .....	195
<i>Mesenchymal stem cells for gene therapy</i> .....	195
<i>Microporation for transfection of MSCs</i> .....	196
<i>Regulation of gene expression for SC-based gene therapy</i> .....	196
<i>Stem cells and in utero gene therapy</i> .....	196
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i> .....	197
<i>Targeted genome editing for human repopulating HSCs</i> .....	197
<i>The future of hematopoietic stem cell gene therapy</i> .....	197
<b>Stem cell pharmaceuticals</b> .....	<b>197</b>
Pharmaceutical manipulation of stem cells .....	198
<i>Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase</i> .....	198
<i>Expansion of HSCs in vivo by use of prostaglandin E2</i> .....	199
<i>Manipulation of stem cells with growth factors</i> .....	199
<i>Mobilization of stem cells by cytokines/chemokines</i> .....	201
<i>Mobilization of adult human HSCs by use of inhibitors</i> .....	202
<i>Mobilization of stem cells by HYC750</i> .....	202
<i>Mobilization of stem cells by hyperbaric oxygen</i> .....	203
<i>Mobilization by adenoviral vectors expressing angiogenic factors</i> .....	203
<i>Stem cell mobilization by acetylcholine receptor agonists</i> .....	203
<i>Use of parathyroid hormone to increase HSC mobilization</i> .....	204
<i>Use of small molecule compounds for expansion of HSCs</i> .....	204
<i>Use of a small molecule for targeting systemically infused MSCs</i> .....	204
Role of stem cells in therapeutic effects of drugs.....	205
Stem cells for drug discovery .....	205
<i>Target identification</i> .....	205
<i>High-throughput screening</i> .....	205
<i>ESCs as source of models for drug discovery</i> .....	206
<i>hESC-derived hepatocytes for drug discovery</i> .....	206
<i>hESC-derived cardiomyocytes for drug discovery</i> .....	207
<i>iPSCs for drug discovery</i> .....	208
<i>Advantages and limitations of use of stem cells for drug discovery</i> .....	208
Stem cells for drug delivery.....	209
Toxicology and drug safety studies using ESCs versus other cells.....	209
<b>Future challenges for stem cell technologies</b> .....	<b>212</b>
Generation of patient-specific pluripotent stem cells.....	212



Hybrid embryos/cybrids for stem cell research.....	213
In vivo study of human hemopoietic stem cells.....	213
Inhibition of stem cell-derived teratoma formation by small molecules.....	213
Markers for characterizing hESC lines.....	214
MBD3-deficient ESC line.....	214
Research into plasticity of stem cells from adults.....	214
Reversion of human stem cells to ground state pluripotency.....	215
Stem cell biology and cancer.....	215
Stem cells and aging.....	216
Stem cells in space.....	217
Study of the molecular mechanism of cell differentiation.....	217
Switch of stem-cell function from activators to repressors.....	218
<b>Stem cell research at academic centers.....</b>	<b>218</b>
International Regulome Consortium.....	219
<b>Companies involved in stem cell technologies.....</b>	<b>220</b>
<b>Concluding remarks about stem cells.....</b>	<b>225</b>
<b>Challenges and prospects of stem cell research.....</b>	<b>225</b>

#### **4. Clinical Applications of Cell Therapy..... 227**

<b>Introduction.....</b>	<b>227</b>
<b>Cell therapy for hematological disorders.....</b>	<b>227</b>
Transplantation of autologous hematopoietic stem cells.....	227
HSCs derived from pluripotent stem cells.....	227
Hemophilias.....	228
<i>Ex vivo cell/gene therapy of hemophilia B.....</i>	<i>228</i>
<i>Cell/gene therapy of hemophilia A.....</i>	<i>229</i>
Hematopoietic stem cell therapy for thrombocytopenia.....	229
Stem cell transplant for sickle cell anemia.....	230
Treatment of chronic acquired anemias.....	230
<i>Implantation of genetically engineered HSCs to deliver rhEpo.....</i>	<i>231</i>
<i>Drugs acting on stem cells for treatment of anemia.....</i>	<i>231</i>
Stem cell therapy of hemoglobinopathies.....	231
<i>iPSC-based therapy for <math>\beta</math>-thalassemia.....</i>	<i>232</i>
Stem cells for treatment of immunoglobulin-light chain amyloidosis.....	232
Future prospects of cell therapy of hematological disorders.....	232
<b>Cell therapy for immunological disorders.....</b>	<b>233</b>
Role of dendritic cells in the immune system.....	233
Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures.....	233
Potential of MSCs as therapy for immune-mediated diseases.....	234
Stem cell therapy of chronic granulomatous disease.....	234
Stem cell therapy of X-linked severe combined immunodeficiency.....	234
Stem cell therapy of autoimmune disorders.....	235
<i>Wiskott-Aldrich Syndrome.....</i>	<i>235</i>
<i>Treatment of rheumatoid arthritis with stem cells.....</i>	<i>235</i>
<i>Treatment of Crohn's disease with stem cells.....</i>	<i>236</i>
<i>Stem cell transplants for scleroderma.....</i>	<i>237</i>
Role of T Cells in immunological disorders.....	237
<i>Autologous T cells from adult stem cells.....</i>	<i>238</i>
Cell therapy for graft vs host disease.....	238
<i>T cell infusion for suppressing GVHD.....</i>	<i>239</i>
<i>Genetically modified Tregs expressing CAR for prevention of GVHD.....</i>	<i>239</i>
<i>MSCs for GVHD.....</i>	<i>240</i>
<b>Cell therapy for viral infections.....</b>	<b>240</b>
Anti-HIV ribozyme delivered in hematopoietic progenitor cells.....	240
Dendritic-cell targeted DNA vaccine for HIV.....	241
Exosomes and viral infections.....	241
Manipulation of T cells for treatment of viral infections.....	241
<i>T cell therapy for CMV.....</i>	<i>241</i>
<i>T cell therapy for HIV infection.....</i>	<i>242</i>
<i>T cell immunity by Overlapping Peptide-pulsed Autologous Cells.....</i>	<i>242</i>
Modification of iPSCs with a mutation to confer resistance to HIV.....	243
<b>Cell therapy of lysosomal storage diseases.....</b>	<b>243</b>
Niemann-Pick disease.....	243
Gaucher's disease.....	244
Fabry's disease.....	244
<b>Cell therapy for endocrine disorders.....</b>	<b>245</b>
Hypopituitarism.....	245
Adrenal insufficiency.....	245
<b>Cell therapy for diabetes mellitus.....</b>	<b>246</b>
Limitations of current treatment.....	247
<i>Limitations of insulin therapy for diabetes mellitus.....</i>	<i>247</i>

<i>Limitations of pancreatic transplantation</i> .....	247
Islet cell transplantation .....	247
<i>Autologous pancreatic islet cell transplantation in chronic pancreatitis</i> .....	248
<i>Clinical trials of pancreatic islet cell transplants for diabetes</i> .....	248
<i>Drawbacks of islet cell therapy</i> .....	249
<i>Use of an antioxidant peptide to improve islet cell transplantation</i> .....	249
<i>Cdk-6 and cyclin D1 enhance human beta cell replication and function</i> .....	249
<i>Devices for delivery of therapeutic cells in diabetes</i> .....	250
<i>Monitoring of islet cell transplants with MRI</i> .....	250
<i>Concluding remarks about allogeneic islet transplantation for diabetes</i> .....	250
Encapsulation of insulin producing cells .....	251
<i>Encapsulated porcine pancreatic islet cells for pancreas</i> .....	251
<i>Encapsulated insulinoma cells</i> .....	252
<i>Magnetocapsule enables imaging/tracking of islet cell transplants</i> .....	252
Islet precursor cells .....	252
Dedifferentiation of $\beta$ cells to promote regeneration .....	253
Pharmacological approaches for $\beta$ cell regeneration .....	253
Xenotransplantation of embryonic pancreatic tissue .....	254
Non-pancreatic tissues for generation of insulin-producing cells .....	254
Exploiting maternal microchimerism to treat diabetes in the child .....	255
Bio-artificial substitutes for pancreas .....	255
Role of stem cells in the treatment of diabetes .....	256
<i>Embryonic stem cells for diabetes</i> .....	256
<i>HSC transplantation to supplement immunosuppressant therapy</i> .....	257
<i>Insulin-producing cells derived from UCB stem cells</i> .....	257
<i>iPSc for diabetes</i> .....	258
<i>Pancreatic stem cells</i> .....	258
<i>Stem cell injection into portal vein of diabetic patients</i> .....	259
Conversion of progenitor cells into insulin-producing cells .....	259
<i>Human neural progenitor cells converted into insulin-producing cells</i> .....	259
<i>Isolation of islet progenitor cells</i> .....	259
<i>Pancreatic progenitor cells</i> .....	260
Cell-based immunotherapy for type 1 diabetes .....	260
<i>Dendritic cell-based therapy</i> .....	260
<i>T regulatory cell therapy for diabetes</i> .....	261
<i>Vaccine for diabetes</i> .....	261
Gene therapy in diabetes .....	261
<i>Viral vectors for gene therapy of diabetes</i> .....	261
<i>Genetically engineered dendritic cells</i> .....	262
<i>Genetically altered liver cells</i> .....	262
<i>Genetically modified stem cells</i> .....	262
Companies developing cell therapy for diabetes .....	263
Concluding remarks about cell and gene therapy of diabetes .....	263
<b>Cell therapy of gastrointestinal disorders .....</b>	<b>265</b>
Inflammatory bowel disease.....	265
<b>Cell therapy for liver disorders .....</b>	<b>265</b>
Types of cells used for hepatic disorders .....	265
<i>Culture and expansion of primary human hepatocytes</i> .....	266
<i>Hepatocyte progenitor cells</i> .....	266
<i>Hybrid periportal hepatocytes</i> .....	267
Methods of delivery of cells for hepatic disorders .....	267
Hepatic failure .....	267
Bioartificial liver.....	268
<i>Hepatocyte-based artificial liver</i> .....	268
<i>Extracorporeal Liver Assist Device</i> .....	268
<i>Limitations of bioartificial liver</i> .....	269
<i>Proliferating cell-based bioartificial liver</i> .....	269
Stem cells for hepatic disorders .....	269
<i>Deriving hepatocytes from commercially available hMSCs</i> .....	270
<i>Implantation of hepatic cells derived from hMSCs of adipose tissue</i> .....	270
<i>Heterologous adult liver progenitor cells</i> .....	270
<i>Liver stem cell culture</i> .....	271
<i>MSC derived molecules for reversing hepatic failure</i> .....	271
Cell-based gene therapy for liver disorders.....	271
<i>Transplantation of genetically modified fibroblasts</i> .....	272
<i>Transplantation of genetically modified hepatocytes</i> .....	272
<i>Genetically modified hematopoietic stem cells</i> .....	272
<i>iPSCs derived from somatic cells for liver regeneration</i> .....	273
<i>Hepatocyte-like cells derived from human parthenogenetic stem cells</i> .....	273
Clinical applications .....	273
Future prospects of cell-based therapy of hepatic disorders.....	274

<b>Cell therapy of renal disorders.....</b>	<b>275</b>
Bioartificial kidney.....	275
Cell-based repair for vascular access failure in renal disease .....	275
Mesangial cell therapy for glomerular disease.....	276
Stem cells for renal disease.....	276
<i>Role of stem cells in renal repair .....</i>	<i>276</i>
<i>Bone marrow stem cells for renal disease .....</i>	<i>277</i>
<i>Human amniotic fluid stem cells for renal regeneration .....</i>	<i>277</i>
<i>MSC therapy for renal disease .....</i>	<i>277</i>
<i>MSCs as aid to renal graft survival .....</i>	<i>278</i>
Transplantation of cell-based bioengineered kidney .....	278
<b>Cell therapy for pulmonary disorders.....</b>	<b>279</b>
Delivery of cell therapy for pulmonary disorders .....	279
<i>Intratracheal injection of cells for pulmonary hypoplasia .....</i>	<i>279</i>
Role of stem cells in pulmonary disorders .....	279
<i>Lung stem cells.....</i>	<i>279</i>
<i>Lung tissue regeneration from stem cells .....</i>	<i>280</i>
<i>Role of autologous MSCs in the treatment of severe emphysema .....</i>	<i>280</i>
<i>Role of stem cells in construction of the Cyberlung.....</i>	<i>280</i>
<i>Respiratory epithelial cells derived from UCB stem cells .....</i>	<i>281</i>
<i>Respiratory epithelial cells derived from hESCs.....</i>	<i>281</i>
<i>Lung tissue engineering with adipose stromal cells.....</i>	<i>281</i>
<i>Cell-based tissue-engineering of airway .....</i>	<i>282</i>
Pulmonary disorders that can be treatable with stem cells .....	283
<i>Acute lung injury and ARDS treated with MSCs.....</i>	<i>283</i>
<i>Bronchopulmonary dysplasia treated with MSCs.....</i>	<i>284</i>
<i>Chronic obstructive pulmonary disease treated with MSCs.....</i>	<i>284</i>
<i>Cystic fibrosis treatment with genetically engineered MSCs .....</i>	<i>285</i>
<i>Idiopathic pulmonary fibrosis.....</i>	<i>285</i>
<i>Lung regeneration by integrin <math>\alpha\beta4</math>-expressing alveolar epithelial cell .....</i>	<i>285</i>
<i>Pulmonary arterial hypertension treatment with EPCs.....</i>	<i>285</i>
<b>Cell therapy for disorders of bones, joints and tendons .....</b>	<b>286</b>
Cell therapy for repair of fractures and bone defects .....	286
<i>Bone regeneration by human very small embryonic-like (hVSEL) cells .....</i>	<i>287</i>
<i>Cell therapy for cervical vertebral interbody fusion .....</i>	<i>288</i>
<i>Cell-mediated gene therapy for bone regeneration .....</i>	<i>288</i>
<i>ESCs for bone repair .....</i>	<i>288</i>
<i>hiPSCs for engineering personalized bone grafts .....</i>	<i>288</i>
<i>Intrauterine use of MSCs for osteogenesis imperfecta.....</i>	<i>288</i>
<i>In vivo bone engineering as an alternative to cell transplantation.....</i>	<i>289</i>
<i>In vivo differentiation of pluripotent stem cells for bone regeneration .....</i>	<i>289</i>
<i>MSCs for repair of bone defects .....</i>	<i>289</i>
<i>MSCs for repair of bone fractures.....</i>	<i>292</i>
<i>Osteoecel .....</i>	<i>293</i>
<i>Stem cells for repairing skull defects .....</i>	<i>293</i>
<i>Stem cell-based bone tissue engineering .....</i>	<i>294</i>
<i>Spinal fusion using stem cell-based bone grafts.....</i>	<i>295</i>
<i>Wnt stimulation to enrich BMMCs for repair of bone fractures .....</i>	<i>295</i>
Cell therapy of tendon injuries.....	295
<i>Autologous tenocyte implantation in rotator cuff injury repair.....</i>	<i>296</i>
<i>Platelet injection for tennis elbow.....</i>	<i>296</i>
Cell-based techniques for cartilage repair and regeneration.....	297
<i>Cartilage generation from stem cells .....</i>	<i>297</i>
<i>Cartilage engineering from iPSCs .....</i>	<i>298</i>
<i>Genetically modified fibroblasts expressing TGF-<math>\beta</math> for cartilage repair .....</i>	<i>298</i>
<i>Juvenile cartilage implant for repair of damage to articular cartilage.....</i>	<i>299</i>
Cell therapy for repair of knee cartilage injuries.....	299
<i>Autologous chondrocyte therapy of the knee .....</i>	<i>300</i>
<i>Meniscus-derived stem cells.....</i>	<i>301</i>
<i>MSC-based constructs for knee joint replacement .....</i>	<i>301</i>
<i>Nanobiotechnology scaffolds for MSC-based cartilage reconstruction .....</i>	<i>301</i>
<i>Role of cells in the repair of anterior cruciate ligament injury.....</i>	<i>302</i>
Osteoporosis .....	302
<i>Stem cell gene therapy for osteoporosis.....</i>	<i>302</i>
Osteoarthritis of the joints .....	303
<i>Autologous cultured chondrocytes.....</i>	<i>303</i>
<i>Autologous intervertebral disc chondrocyte transplantation .....</i>	<i>304</i>
<i>Intraarticular MSCs for osteoarthritis .....</i>	<i>305</i>
<i>Mosaicplasty.....</i>	<i>305</i>
<i>Stem cell therapy of osteoarthritis of the knee.....</i>	<i>305</i>
Osteonecrosis.....	306

<i>Cell therapy for osteonecrosis</i> .....	306
<i>Cell therapy for radionecrosis</i> .....	306
<i>Repair of osteonecrosis by bone marrow derived MSCs</i> .....	307
Rheumatoid arthritis.....	307
<b>Cell therapy for diseases of the eye</b> .....	<b>307</b>
Cell therapy for corneal repair .....	308
Lens regeneration from endogenous stem cells.....	309
Stem cell therapy for limbal stem cell deficiency .....	309
Role of stem cells in fibrosis following eye injury.....	310
<b>Stem cell transplantation for radiation sickness</b> .....	<b>310</b>
MSCs for treatment of radiation damage to the bone.....	311
MSCs for regeneration of ovaries following radiotherapy damage .....	311
<b>Cell therapy for wound healing</b> .....	<b>311</b>
Cells to form skin substitutes for healing ulcers .....	312
CellSpray for wound repair.....	312
Cell therapy for burns.....	313
Closure of incisions with laser guns and cells .....	314
Genetically engineered keratinocytes for wound repair .....	314
MSCs for wound healing.....	314
Role of amniotic fluid MSCs in repair of fetal wounds .....	315
<b>Role of cells in regenerative medicine</b> .....	<b>315</b>
Stem cells for regeneration of skin and appendages .....	315
<i>Bifunctional ectodermal stem cells and nail regeneration</i> .....	315
<i>Stem cells for regeneration of skin in junctional epidermolysis bullosa</i> .....	315
<i>Follicular stem cells for skin and wound repair</i> .....	316
<i>Regeneration of aging skin by adipose-derived stem cells</i> .....	317
<i>Reprogramming autologous stem cells for regeneration of skin</i> .....	317
<i>Concluding remarks on regeneration of skin by stem cells</i> .....	317
Cell therapy for regeneration of muscle wasting.....	317
Role of stem cells in regeneration of esophageal epithelium .....	318
Stem cell-based regenerative therapy for xerostomia .....	318
Concluding remarks for use of cells in regenerative medicine.....	318
<i>Genomic studies for examining the role of stem cells in regeneration</i> .....	319
<i>Cell therapy for regenerating organs</i> .....	319
<i>Umbilical cord blood for regeneration</i> .....	320
Future prospects of stem cells for regenerative medicine .....	320
<b>Role of cells in tissue engineering and reconstructive surgery</b> .....	<b>321</b>
Scaffolds for tissue engineering .....	321
Improving vascularization of engineered tissues .....	321
<i>Reconstruction of vasculature</i> .....	321
Repair of aging skin by injecting autologous fibroblasts .....	322
Enhancing vascularization by combining cell and gene therapy .....	322
Nanobiotechnology applied to cells for tissue engineering .....	323
Choosing cells for tissue engineering .....	323
Stem cells for tissue repair.....	324
<i>ESCs vs adult SCs for tissue engineering</i> .....	324
<i>Use of adult MSCs for tissue engineering</i> .....	325
<i>Measuring MSC interactions with environment for tissue engineering</i> .....	325
Stem cells for tissue engineering of various organs .....	326
<i>Breast reconstruction by adipose tissue-derived stem cells</i> .....	326
<i>Engineering of healthy living teeth from stem cells</i> .....	326
<i>Intra-uterine repair of congenital defects using amniotic fluid MSCs</i> .....	327
<i>Skin regeneration by stem cells as an alternative to face transplant</i> .....	328
<i>Tissue engineering of bone by stem cells</i> .....	328
Cell-based tissue engineering in genitourinary system .....	329
<i>Urinary incontinence</i> .....	329
<i>Tissue engineering of urinary bladder</i> .....	330
<i>Label retaining urothelial cells for bladder repair</i> .....	331
<i>MSCs for bladder repair</i> .....	331
<i>Tissue-engineering of urethra using autologous cells</i> .....	331
<i>Repair of the pelvic floor with stem cells from the uterus</i> .....	332
<i>Reconstruction of vagina from stem cells</i> .....	332
Reconstruction of cartilage for repair of craniofacial defects.....	332
<b>Intraoperative cell therapy</b> .....	<b>333</b>
<b>Cell therapy for rejuvenation</b> .....	<b>333</b>
Reversal of muscle weakness and atrophy in aging .....	334
Reversal of cognitive impairment in aging .....	334
<b>Cell therapy for performance enhancement in sports</b> .....	<b>334</b>
<b>Application of stem cells in veterinary medicine</b> .....	<b>334</b>
Use of stem cells to repair tendon injuries.....	334
Stem cells for spinal cord injury in dogs.....	335

<b>5. Cell Therapy for Cardiovascular Disorders .....</b>	<b>337</b>
<b>Introduction to cardiovascular disorders .....</b>	<b>337</b>
<b>Limitations of current therapies for myocardial ischemic disease.....</b>	<b>337</b>
<b>Types of cell therapy for cardiovascular disorders.....</b>	<b>337</b>
Cell-mediated immune modulation for chronic heart disease .....	339
Inducing the proliferation of cardiomyocytes .....	339
Pericardial origin of colony-forming units .....	340
Role of splenic myocytes in repair of the injured heart.....	340
Reprogramming of fibroblasts into functional cardiomyocytes .....	340
Stem cell-based therapies for cardiovascular diseases .....	341
<i>Human cardiovascular progenitor cells.....</i>	<i>341</i>
<i>Human pluripotent stem cell-derived cardiomyocytes .....</i>	<i>342</i>
<i>Magnetic antibody-linked nanoparticles to deliver cells to the heart.....</i>	<i>342</i>
<i>Role of the SDF-1-CXCR4 axis in therapies for myocardial ischemia.....</i>	<i>342</i>
<i>Small molecules to enhance myocardial repair by stem cells.....</i>	<i>342</i>
<i>Stem cells and atherosclerosis.....</i>	<i>343</i>
<b>Cell therapy for atherosclerotic coronary artery disease.....</b>	<b>343</b>
MyoCell™ (Bioheart).....	344
Cardiac stem cells .....	344
Cardiomyocytes derived from epicardium.....	345
Cardiac atrial appendage stem cells .....	346
<b>Methods of delivery of cells to the heart .....</b>	<b>346</b>
Cellular cardiomyoplasty .....	346
IGF-1 delivery by nanofibers to improve cell therapy for MI.....	346
Non-invasive delivery of cells to the heart by Morph@guide catheter.....	347
<b>Cell therapy for cardiac revascularization .....</b>	<b>347</b>
Transplantation of cardiac progenitor cells for revascularization of myocardium .....	347
Stem cells to prevent restenosis after coronary angioplasty.....	347
<b>Role of cells in cardiac tissue repair.....</b>	<b>348</b>
Modulation of cardiac macrophages for repair of infarct .....	348
Transplantation of myoblasts for myocardial infarction.....	348
Patching myocardial infarction with fibroblast culture .....	349
Cardiac repair with myoendothelial cells from skeletal muscle .....	350
Myocardial tissue engineering.....	350
<b>Role of stem cells in repair of the heart .....</b>	<b>351</b>
Role of stem cells in cardiac regeneration following injury .....	351
Cardiomyocytes derived from adult skin cells .....	351
Cardiomyocytes derived from ESCs .....	352
Cardiomyocyte differentiation from hIPSCs .....	354
Studies to identify subsets of progenitor cells suitable for cardiac repair .....	354
Technologies for preparation of stem cells for cardiovascular therapy .....	354
<i>Pravastatin for expansion of endogenous progenitor and stem cells.....</i>	<i>354</i>
<i>Cytokine preconditioning of human fetal liver CD133+ SCs .....</i>	<i>355</i>
<i>Expansion of adult cardiac stem cells for transplantation.....</i>	<i>355</i>
<i>Role of MSCs in growth of CSCs.....</i>	<i>356</i>
Role of ESCs in repair of the heart .....	356
<i>ESC transplantation for tumor-free repair of the heart.....</i>	<i>357</i>
Transplantation of stem cells for myocardial infarction.....	357
<i>Autologous bone marrow-derived stem cell therapeutics .....</i>	<i>357</i>
<i>Autologous bone marrow-derived mesenchymal precursor stem cells .....</i>	<i>358</i>
<i>Intracoronary infusion of mobilized peripheral blood stem cells.....</i>	<i>358</i>
<i>Transplantation of cord blood stem cells .....</i>	<i>359</i>
<i>Transplantation of hESCs.....</i>	<i>359</i>
<i>Transplantation of HSCs.....</i>	<i>359</i>
<i>Transplantation of autologous angiogenic cell precursors .....</i>	<i>360</i>
<i>Transplantation of adipose-derived stem cells.....</i>	<i>360</i>
<i>Transplantation of bone marrow-derived cells for myocardial infarct.....</i>	<i>361</i>
<i>Transplantation of human umbilical cord perivascular cells.....</i>	<i>362</i>
<i>Transplantation of endothelial cells.....</i>	<i>362</i>
<i>Transplantation of cardiomyocytes differentiated from hESCs .....</i>	<i>363</i>
Stem cell therapy for cardiac regeneration .....	363
<i>3D printed scaffold for regeneration of myocardial infarct with cells.....</i>	<i>363</i>
<i>Cryopreserved hESC-derived cardiomyocytes for cardiac regeneration.....</i>	<i>364</i>
<i>HSCs for regeneration of the chronic myocardial infarcts.....</i>	<i>364</i>
<i>Human MSCs for cardiac regeneration .....</i>	<i>364</i>
<i>In vivo tracking of MSCs transplanted in the heart .....</i>	<i>365</i>
<i>MSCs for hibernating myocardium.....</i>	<i>366</i>
<i>Simultaneous transplantation of MSCs and skeletal myoblasts .....</i>	<i>366</i>
<b>Transplantation of genetically modified cells.....</b>	<b>366</b>
Transplantation of genetically modified MSCs .....	366
Transplantation of cells secreting vascular endothelial growth factor .....	367

Transplantation of genetically modified bone marrow stem cells.....	367
<b>Cell transplantation for congestive heart failure.....</b>	<b>367</b>
AngioCell gene therapy for congestive heart failure .....	368
Injection of adult stem cells for CHF .....	368
Intracoronary infusion of cardiac stem cells .....	369
Myoblasts for treatment of congestive heart failure .....	369
Stem cell therapy for dilated cardiac myopathy.....	369
<b>Role of cell therapy in cardiac arrhythmias.....</b>	<b>370</b>
Biological pacemakers .....	370
<i>Stem cells as biological pacemakers</i> .....	370
<i>Stem cells for cardiac arrhythmias</i> .....	372
Prevention of myoblast-induced arrhythmias by genetic engineering .....	372
Ventricular tachycardia .....	372
<b>ESCs for correction of congenital heart defects .....</b>	<b>373</b>
<b>Cardiac progenitors cells for treatment of heart disease .....</b>	<b>373</b>
<b>Autologous stem cells for chronic myocardial ischemia .....</b>	<b>374</b>
<b>Role of cells in cardiovascular tissue engineering.....</b>	<b>374</b>
Cell-based in vitro regeneration of heart for transplantation .....	374
Construction of blood vessels with cells .....	375
<i>Engineered arteries for bypass grafts</i> .....	375
Engineering heart valves with UCB progenitor cells .....	376
Epicardial regeneration from hPSCs.....	376
Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts.....	376
Targeted delivery of endothelial progenitor cells labeled with nanoparticles .....	376
<b>Cell therapy for peripheral vascular disease .....</b>	<b>377</b>
ALD-301 .....	377
Cell/gene therapy for PVD .....	377
Cell therapy for CLI in diabetics .....	377
Colony stimulating factors for enhancing peripheral blood stem cells .....	378
Intramuscular autologous bone marrow cells.....	378
Ixmyelocel-T cell therapy for critical limb ischemia.....	378
Stem cell-coated vascular grafts for femoral-tibial arterial bypass .....	379
<b>Clinical trials of cell therapy in cardiovascular disease .....</b>	<b>379</b>
<b>Mechanism of the benefit of cell therapy for heart disease.....</b>	<b>382</b>
<b>A critical evaluation of cell therapy for heart disease .....</b>	<b>382</b>
Publications of clinical trials of cell therapy for CVD .....	383
Current status of cell therapy for cardiovascular disease .....	383
<b>Future directions for cell therapy of CVD .....</b>	<b>384</b>
Combination of cells with biomedical scaffolds .....	384
Prospects of adult stem cell therapy for repair of heart .....	384
Role of cells in regeneration of the heart.....	385
Regeneration of cardiomyocytes without use of cardiac stem cells.....	385
<b>6. Cell Therapy for Cancer.....</b>	<b>387</b>
<b>Introduction .....</b>	<b>387</b>
<b>Cell therapy technologies for cancer.....</b>	<b>387</b>
<b>Cell-based delivery of anticancer therapy .....</b>	<b>388</b>
<b>Cellular immunotherapy for cancer.....</b>	<b>388</b>
Treatments for cancer by ex vivo mobilization of immune cells .....	389
Granulocytes as anticancer agents .....	389
Neutrophil granulocytes in antibody-based immunotherapy of cancer .....	390
<b>Cancer vaccines .....</b>	<b>390</b>
Autologous tumor cell vaccines .....	390
<i>BIOVAXID</i> .....	390
<i>OncoVAX</i> .....	391
<i>Tumor cells treated with dinitrophenyl</i> .....	391
Vaccines that simultaneously target different cancer antigens .....	391
Gene modified cancer cells vaccines .....	392
<i>GVAX cancer vaccines</i> .....	392
<i>K562/GM-CSF</i> .....	392
Active immunotherapy based on antigen specific to the tumor.....	393
The use of dendritic cells for cancer vaccination.....	393
<i>Autologous dendritic cells loaded ex vivo with telomerase mRNA</i> .....	393
<i>Dendritic cell-targeted protein vaccines</i> .....	394
<i>Dendritic/tumor cell fusion</i> .....	394
<i>Electro-hyperthermia for improving DC immunotherapy</i> .....	394
<i>Genetically modified dendritic cells</i> .....	395
<i>In vivo manipulation of dendritic cells</i> .....	395
<i>Preclinical and clinical studies with DC vaccines</i> .....	395
<i>Vaccines based on dendritic cell-derived exosomes</i> .....	396
<i>Limitations of DC vaccines for cancer</i> .....	396

<i>Future developments to enhance clinical efficacy of DC vaccines</i> .....	397
Cell-based cancer immunotherapy .....	398
<i>Adoptive cell therapy</i> .....	398
<i>CD8+ T cells for use in tumor immunotherapy</i> .....	399
<i>Chimeric antigen receptor T cells</i> .....	400
<i>ProCAR-NK cancer immunotherapy</i> .....	402
<i>Combination of antiangiogenic agents with ACT</i> .....	403
<i>Expansion of antigen-specific cytotoxic T lymphocytes</i> .....	403
<i>Genetically modified T cells for targeting tumors</i> .....	403
<i>Genetic engineering of tumor cells to activate T helper cells</i> .....	404
<i>Targeting T regulatory cells</i> .....	404
<i>T cells with immunological memory and stem cell-like properties</i> .....	404
<i>Tumor infiltrating lymphocytes</i> .....	405
Hybrid cell vaccination .....	405
Chemoimmunotherapy .....	406
<b>Stem cell-based anticancer therapies</b> .....	<b>406</b>
Stem cell transplantation in cancer .....	406
<i>Peripheral blood stem cell transplantation</i> .....	406
<i>Stem cell transplantation for hematological malignancies</i> .....	409
<i>Long-term results of HSC transplantation</i> .....	410
<i>Prediction of T cell reconstitution after HSC transplantation</i> .....	411
<i>HSC transplantation followed by GM-CSF-secreting cell vaccines</i> .....	411
<i>HSC transplantation for renal cell cancer</i> .....	412
<i>Umbilical cord blood transplant for hematological malignancies</i> .....	412
Complications of stem cell transplants in cancer .....	413
<i>Graft-versus-host disease (GVHD)</i> .....	413
<i>Delayed immune reconstitution leading to viral infections and relapse</i> .....	413
<i>Tumor cell contamination</i> .....	413
<i>Neurological complications</i> .....	414
<i>Hepatic veno-occlusive disease</i> .....	414
<i>Current status and safety of allogeneic HSC transplantation</i> .....	414
<i>Complications of PBSC transplantation in children</i> .....	415
Role of MSCs in cancer .....	416
<i>MSC-mediated delivery of anticancer therapeutics</i> .....	416
<i>Mesenchymal progenitor cells for delivery of oncolytic adenoviruses</i> .....	416
<i>MSCs for oncolytic HSV delivery for brain metastases of melanoma</i> .....	417
Nonmyeloablative allogeneic hematopoietic stem cell transplantation .....	417
hESC-derived NK cells for treatment of cancer .....	418
ESC vaccine for prevention of lung cancer .....	418
Genetic modification of stem cells for cancer therapy .....	418
<i>Genetic modification of hematopoietic stem cells</i> .....	418
<i>Use of hematopoietic stem cells to deliver suicide genes to tumors</i> .....	419
<i>Delivery of anticancer agents by genetically engineered MSCs</i> .....	419
<i>Genetically modified NSCs for treatment of neuroblastoma</i> .....	420
<b>Innovations in cell-based therapy of cancer</b> .....	<b>420</b>
Use of immortalized cells .....	420
Cancer therapy based on natural killer cells .....	421
Cytokine-induced killer cells .....	421
Mesothelin as a target for cancer immunotherapy .....	421
Nanomagnets for targeted cell-based cancer gene therapy .....	422
Implantation of genetically modified encapsulated cells for anticancer therapy .....	422
<i>Antiangiogenesis therapy by implantation of microencapsulated cells</i> .....	422
<i>Recombinant tumor cells secreting fusion protein</i> .....	422
<i>A device for filtering cancer and stem cells in the blood</i> .....	422
Cancer stem cells .....	423
<i>Cancer stem cell biomarkers</i> .....	423
<i>Integrative nuclear signaling and development of cancer in stem cells</i> .....	424
<i>Origin of cancer in normal stem cells</i> .....	424
<i>Role of intestinal stem cells in intestinal polyposis</i> .....	424
<i>Role of endothelial progenitor cells in tumor angiogenesis</i> .....	425
<i>Role of cancer stem cells in metastases</i> .....	425
<i>Therapeutic implications of cancer stem cells</i> .....	425
<i>Targeting breast cancer stem cells</i> .....	426
<i>Targeting cancer stem cells in leukemia</i> .....	427
<i>Targeting cancer stem cells in ovarian cancer</i> .....	427
<i>Targeting cancer stem cells to screen anticancer drugs</i> .....	428
<b>Companies involved in cell-based cancer therapy</b> .....	<b>428</b>
<b>American Association for Cancer Research and ESCs</b> .....	<b>429</b>
<b>Future of cell-based immunotherapy for cancer</b> .....	<b>430</b>

## **7. Cell Therapy for Neurological Disorders..... 432**

<b>Introduction .....</b>	<b>432</b>
<b>Use of stem cells for research in neurosciences.....</b>	<b>432</b>
Cerebral organoids for modeling human brain development .....	432
Use of human stem cell-derived neurons in neuropharmacology .....	432
<b>Regeneration of brain by in vitro/in vivo reprogramming of cells.....</b>	<b>433</b>
Molecular mechanism of neurogenesis .....	434
Generation of neurons from astroglia .....	435
In vivo cell replacement therapy by locally induced neural progenitor cells.....	435
In vivo reprogramming to generate new neurons.....	435
<b>Types of cells used for treatment of neurological disorders.....</b>	<b>436</b>
Activated T lymphocytes .....	437
Differentiation of placenta-derived multipotent cells into neurons.....	437
Fibroblast-derived human striatal neurons .....	437
Mesenchymal stem cells induced to secrete neurotrophic factors.....	437
MUSE cells transplantation for neuronal regeneration .....	438
Neural stem cells .....	438
<i>Development of human CNS stem cells.....</i>	<i>438</i>
<i>Direct conversion of adult fibroblasts into neural progenitor cells .....</i>	<i>439</i>
<i>Distinction between NSCs and intermediate neural progenitors.....</i>	<i>439</i>
<i>Embryonic stem cell-derived neurogenesis.....</i>	<i>439</i>
<i>Epidermal neural crest stem cells for neurological disorders .....</i>	<i>440</i>
<i>Fusion of NSCs with endogenous neurons .....</i>	<i>440</i>
<i>Induction of NSCs from hESCs.....</i>	<i>440</i>
<i>Induction of NSCs from adult MSCs.....</i>	<i>442</i>
<i>Mechanism of migration of NSCs to sites of CNS injury .....</i>	<i>442</i>
<i>Monitoring of implanted NSCs labeled with nanoparticles .....</i>	<i>442</i>
<i>Neural progenitor cells.....</i>	<i>442</i>
<i>Neural stem cells in the subventricular zone of the brain.....</i>	<i>445</i>
<i>Oligodendrocyte progenitor cells.....</i>	<i>445</i>
<i>Promotion of neural stem cells expansion by betacellulin .....</i>	<i>445</i>
<i>Proteomics of neural stem cells.....</i>	<i>445</i>
<i>Regulation of neural stem cells in the brain .....</i>	<i>446</i>
<i>Role of CSF proteins in regulation of neural progenitor cells .....</i>	<i>447</i>
<i>Sequencing the transcriptomes of neural stem cells .....</i>	<i>447</i>
<i>Study of neural differentiation of hESCs by NeuroStem Chip.....</i>	<i>448</i>
<i>Transformation of neural stem cells into other cell types.....</i>	<i>448</i>
Stem cell transplantation in the CNS .....	448
<i>Development of CNS cells from non-CNS stem cells .....</i>	<i>448</i>
<i>Expansion of adult human neural progenitors.....</i>	<i>449</i>
<i>Hair-follicle stem cells for neural repair.....</i>	<i>449</i>
<i>Human NSCs for treatment of neurological disorders.....</i>	<i>450</i>
<i>NSCs and scaffolds for regeneration therapy of CNS disorders.....</i>	<i>451</i>
<i>Neurospheres.....</i>	<i>451</i>
<i>Stem cells from olfactory epithelium for transplantation in the CNS.....</i>	<i>451</i>
<i>Stem cells from human umbilical cord blood for CNS disorders .....</i>	<i>451</i>
Choroid plexus cells for transplantation.....	452
Dental pulp cells for neuroprotection .....	452
Derivation of CNS cells from peripheral nervous system.....	452
Fetal tissue transplants.....	453
Immortalized cells for CNS disorders .....	453
Laboratory mice with human brain cells.....	454
Olfactory ensheathing cells for CNS repair.....	454
Ideal cells for transplantation into the nervous system .....	455
<b>Cell therapy techniques for neurological applications.....</b>	<b>455</b>
Carbon nanotubes to aid stem cell therapy of neurological disorders .....	455
Cell transplantation for regeneration of the nervous system .....	455
Cells used for gene therapy of neurological disorders.....	456
<i>Fibroblasts .....</i>	<i>456</i>
<i>Stem cells.....</i>	<i>456</i>
<i>Neuronal cells.....</i>	<i>457</i>
<i>Immortalized neural progenitor cells .....</i>	<i>457</i>
<i>Astrocytes.....</i>	<i>457</i>
<i>Cerebral endothelial cells .....</i>	<i>458</i>
<i>Human retinal pigmented epithelial cells .....</i>	<i>458</i>
Enhancement of growth of stem cells in the brain by drugs .....	458
<i>C3-induced differentiation and migration of NPC for repair of the brain .....</i>	<i>459</i>
Stem cell therapies of neurological disorders combined with HBO.....	459
hESCs for CNS repair.....	460
Motor neurons derived from stem cells .....	460
MSCs for CNS repair.....	460
Neuronal differentiation of stem cells.....	461



<i>Apigenin promotes differentiation of stem cells into neural lineage</i> .....	462
Stem cells preparations for CNS disorders .....	462
Tracking of stem cells in the CNS by nanoparticles and MRI .....	463
Use of neural stem cells to construct the blood brain barrier .....	463
Methods of delivery of cells to the CNS .....	464
<i>Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders</i> .....	464
<i>CNS delivery of cells by catheters</i> .....	464
<i>Engineered stem cells for drug delivery to the brain</i> .....	465
<i>Encapsulated cells</i> .....	465
<i>Intrathecal delivery of stem cells</i> .....	465
<i>Intraparenchymal delivery of stem cells to the spinal cord</i> .....	466
<i>Intravascular administration</i> .....	466
<i>Neural stem cells as therapeutic delivery vehicles</i> .....	467
<b>Neurological disorders amenable to cell therapy</b> .....	<b>467</b>
Neuroprotection by cell therapy .....	468
<i>Cells secreting neuroprotective substances</i> .....	468
<i>Stem cells for neuroprotection</i> .....	468
<i>Neuroprotection by intravenous administration of HSCs</i> .....	468
<i>Human UCB-derived stem cells for the aging brain</i> .....	468
Neurodegenerative disorders .....	469
<i>MSCs for therapy of neurodegenerative disorders</i> .....	469
<i>Role of stem cells in neurodegenerative disorders</i> .....	470
<i>Role of NSCs in disorders associated with aging brain</i> .....	471
<i>NSCs for improving memory</i> .....	471
Parkinson's disease .....	471
<i>Cell therapies for PD</i> .....	472
<i>Delivery of cells for PD</i> .....	473
<i>Dopamine neurons for PD</i> .....	474
<i>Encapsulated cells for PD</i> .....	474
<i>Graft survival-enhancing drugs</i> .....	475
<i>Human retinal pigment epithelium cells for PD</i> .....	475
<i>Potential of regeneration of endogenous stem cells in PD</i> .....	476
<i>Pluripotent stem cell-derived neurons</i> .....	476
<i>Stem cell transplantation in animal models of PD</i> .....	477
<i>Stem cells for production of glial derived neurotrophic factor</i> .....	478
<i>Transplantation of embryonic medial ganglionic eminence cells</i> .....	479
<i>Trials of stem cell transplantation in PD patients</i> .....	479
<i>Tumorigenic potential of transplanted dopaminergic hESCs</i> .....	480
<i>Xenografting porcine fetal neurons</i> .....	481
<i>Personalized stem cell therapy for PD</i> .....	481
<i>Future perspectives of clinical trials of stem cell therapy for PD</i> .....	482
MSCs for multiple system atrophy .....	482
Cell therapy for Huntington's disease.....	483
<i>Fetal striatal cell transplantation</i> .....	483
<i>Transplantation of encapsulated porcine choroids plexus cells</i> .....	483
<i>iPSCs for HD</i> .....	484
<i>Mobilization of endogenous neural progenitor cells in HD</i> .....	484
Cell therapy for Alzheimer's disease .....	484
<i>Choroid plexus epithelial cells for AD</i> .....	484
<i>Implantation of genetically engineered cells producing NGF</i> .....	485
<i>Implantation of stem cells derived from the skin</i> .....	485
<i>Neural stem cell implantation for Alzheimer's disease</i> .....	485
Cell therapy for amyotrophic lateral sclerosis.....	486
<i>Stem cell techniques for study of ALS</i> .....	486
<i>Rational for use of stem cells for ALS</i> .....	487
<i>Experimental studies with various types of stem cells for ALS</i> .....	487
<i>Clinical trials of stem cells for ALS</i> .....	489
<i>Transplantation of glial restricted precursors in ALS</i> .....	490
<i>Stem cell-based drug discovery for ALS</i> .....	490
Cell therapy for demyelinating disorders .....	491
<i>Autologous bone marrow stem cell therapy for multiple sclerosis</i> .....	491
<i>ESCs for remyelination</i> .....	491
<i>Fusokine method of personalized cell therapy of MS</i> .....	492
<i>Genetically engineered macrophages expressing Nav1.5</i> .....	492
<i>Hematopoietic stem cell transplantation for MS</i> .....	492
<i>Mechanism of repair of demyelination after NSC transplantation</i> .....	493
<i>MSCs for multiple sclerosis</i> .....	493
<i>Neural progenitor cells for neuroprotection in MS</i> .....	494
<i>Oligodendrocyte generation from human iPSCs</i> .....	494
<i>T cell-based personalized vaccine for MS</i> .....	495
<i>Stem cells for chronic inflammatory demyelinating polyneuropathy</i> .....	495

<i>Stem cell transplantation for Pelizaeus-Merzbacher disease</i> .....	495
<i>X-linked adrenoleukodystrophy</i> .....	496
Cell therapy of stroke .....	496
<i>Adult stem cell therapy in stroke</i> .....	497
<i>Cell therapy of intracerebral hemorrhage</i> .....	497
<i>Implantation of genetically programmed ESCs</i> .....	498
<i>Intravenous infusion of MSCs</i> .....	498
<i>Intravenous infusion of human UCB stem cells</i> .....	499
<i>Intracerebral administration of human adipose tissue stromal cells</i> .....	499
<i>Neural stem cell therapy for stroke</i> .....	500
<i>Transplantation of encapsulated porcine choroids plexus</i> .....	501
<i>Transplantation of fetal porcine cells</i> .....	501
<i>Role of cell therapy in management of stroke according to stage</i> .....	501
<i>Clinical trials of cell therapy for stroke</i> .....	502
<i>Future of cell therapy for stroke</i> .....	503
Cell therapy of traumatic brain injury .....	504
<i>Cell/gene therapy for TBI</i> .....	505
<i>Clinical trials of autologous stem cell therapy for TBI</i> .....	505
<i>Limitations of stem cell therapy for acute TBI</i> .....	506
<i>Improving the microenvironments of transplanted cells in TBI</i> .....	506
<i>MSC-derived exosomes for treatment of TBI</i> .....	506
Cell therapy for spinal cord injury .....	507
<i>Autoimmune T cells against CNS myelin-associated peptide</i> .....	507
<i>Fetal neural grafts for SCI</i> .....	507
<i>Olfactory-ensheathing cells for SCI</i> .....	507
<i>Oligodendrocyte precursor cells for treatment of SCI</i> .....	508
<i>Schwann cell transplants for SCI</i> .....	508
<i>Transplantation of glial cells for SCI</i> .....	508
Stem cells for SCI .....	509
<i>Bone marrow stem cells for SCI</i> .....	509
<i>Embryonic stem cells for SCI</i> .....	509
<i>ESC-derived neural aggregates for treatment of SCI</i> .....	510
<i>Transplantation of induced pluripotent stem cells in SCI</i> .....	511
<i>Transplantation of MSCs for SCI</i> .....	511
<i>Transplantation of NSCs for SCI</i> .....	511
<i>Transplantation of human dental pulp stem cells</i> .....	512
<i>Transdifferentiation of BM stem cells into cholinergic neurons for SCI</i> .....	512
<i>Evaluation of experimental studies of stem cell transplantation in SCI</i> .....	513
Spinal stem cells for treatment of ischemic injury of spinal cord .....	513
Combined approaches for regeneration in SCI .....	513
<i>Combined cell/gene therapy for SCI</i> .....	514
Delivery of cells in SCI .....	514
<i>Intrathecal injection of cells labeled with magnetic nanoparticles</i> .....	515
<i>Intravenous injection of stem cells for spinal cord repair</i> .....	515
Clinical applications of stem cells for SCI .....	515
<i>Autologous bone marrow cell transplantation for SCI</i> .....	515
<i>Cell therapy of syringomyelia</i> .....	516
Cell therapy for neurogenetic disorders .....	516
<i>Hurler's syndrome treated with stem cells</i> .....	516
<i>Krabbe's disease treated with UCB stem cells</i> .....	517
<i>Krabbe's disease treated with combination of cell and gene therapy</i> .....	517
<i>Mitochondrial encephalomyopathies treated with stem cells</i> .....	518
<i>Sanfilippo syndrome type B treated with UCB stem cells</i> .....	518
Cell therapy for lysosomal storage disorders .....	519
<i>Cell therapy for Batten disease</i> .....	519
<i>Cell/gene therapy for Farber's disease</i> .....	519
<i>Genetically modified HSCs for metachromatic leukodystrophy</i> .....	520
<i>Neural stem cells for lysosomal storage disorders</i> .....	520
Cell therapy of epilepsy .....	520
<i>Cell therapy of posttraumatic epilepsy</i> .....	521
<i>Cell therapy for temporal lobe epilepsy</i> .....	521
<i>Cell therapy for pharmaco-resistant epilepsies</i> .....	521
Cell therapy for developmental neurological disorders .....	522
Cell therapy for cerebral palsy .....	522
Cell-based therapies for malignant CNS tumors .....	523
<i>Bone morphogenetic protein for inhibition of glioblastoma multiforme</i> .....	523
<i>Dendritic cell therapy for brain tumors</i> .....	523
<i>Encapsulated cells for brain tumors</i> .....	524
<i>Engineered human NSCs for treatment of spinal cord gliomas</i> .....	524
<i>Immunotherapy of GBM targeting cancer stem cells</i> .....	525
<i>Mesenchymal stem cells for the treatment of gliomas</i> .....	525

<i>Neural stem cells for treatment of malignant brain tumors</i> .....	526
<i>Role of cancer stem cells in resistance to radiotherapy</i> .....	527
<i>Stem cell-based therapy targeting EGFR in GBM</i> .....	528
<i>Targeting stem cells in brain tumors</i> .....	528
<i>Clinical trials of cell therapy of glioblastoma multiforme</i> .....	528
Cell therapy for chemobrain .....	528
Cell therapy for muscle disorders .....	529
<i>Duchenne muscular dystrophy</i> .....	529
<i>Combination of cell and pharmacotherapy for DMD</i> .....	530
<i>Myoblast transplant for DMD</i> .....	530
<i>Myoblast-based gene transfer</i> .....	530
<i>Myoblasts lacking the MyoD gene</i> .....	531
<i>Myoblast injection for treatment of other muscular dystrophies</i> .....	531
<i>Role of satellite cells in the treatment of DMD</i> .....	531
<i>Stem cells for DMD</i> .....	532
<i>Wnt7a treatment for DMD</i> .....	534
Cell therapy for autism .....	534
Management of chronic intractable pain by cell therapy .....	534
<i>Implantation of chromaffin cells</i> .....	535
<i>Role of stem cells in management of pain</i> .....	535
<i>Implantation of astrocytes secreting enkephalin</i> .....	536
<i>Cells for delivery of antinociceptive molecules</i> .....	536
<i>Implantation of genetically engineered cells</i> .....	536
<i>Cell therapy for low back pain</i> .....	536
Cell therapy for neuropathic itch .....	537
Cell therapy for neuroendocrine disorders .....	537
<i>Pituitary stem cells</i> .....	537
Cell therapy for regenerating optic pathways.....	538
Cell therapy for retinal degenerative disorders.....	538
<i>Delivery of CNTF by encapsulated cell intraocular implants</i> .....	539
<i>Genetically engineered retinal pigmented epithelial cell lines</i> .....	539
Stem cell-based therapies for retinal degenerative disorders .....	539
<i>Adipose-derived stem cells for retinal degeneration</i> .....	540
<i>Adipose-derived stem cells transplantation for diabetic retinopathy</i> .....	540
<i>ESCs for retinal degenerative disorders</i> .....	540
<i>hESC-derived RPE cells for macular dystrophy</i> .....	540
<i>Human retinal stem cells</i> .....	541
<i>iPSCs for AMD</i> .....	541
<i>Neuroprotective effect of neural progenitor cell transplantation</i> .....	542
<i>Stem-cell based therapy for retinitis pigmentosa</i> .....	543
<i>Stem cell transplantation in the retina</i> .....	543
<i>Combining stem cell and gene therapies for retinal disorders</i> .....	543
Clinical trials of cell therapy for retinal degenerative disorders .....	544
Stem cell therapy for hearing loss .....	544
Cell therapy for peripheral nerve lesions.....	545
<i>Cell transplants for peripheral nerve injuries</i> .....	545
<i>Role of adipose-derived stem cells in peripheral nerve regeneration</i> .....	545
<i>Treatment of diabetic neuropathy with endothelial progenitor cells</i> .....	546
<b>Complications of cell therapy of neurological disorders</b> .....	<b>546</b>
Tumor formation after CNS transplantation of stem cells.....	546
<i>Donor stem cell-derived brain tumor</i> .....	546
<i>Glioproliferative lesion of spinal cord as a complication of cell therapy</i> .....	546
<i>Uncontrolled differentiation of implanted ESCs</i> .....	547
Tumorigenicity of ESC-derived retinal progenitor cells .....	547
<b>Clinical trials of cell therapy in neurological disorders</b> .....	<b>547</b>
<b>Future of cell therapy of CNS disorders</b> .....	<b>549</b>
<b>8. Ethical, Legal and Political Aspects of Cell therapy</b> .....	<b>552</b>
<b>Introduction</b> .....	<b>552</b>
<b>Political and ethical aspects of hESC research in the US</b> .....	<b>552</b>
Ethical issues concerning fetal tissues.....	553
<i>Morality and hESC research</i> .....	553
Opponents of hESC research in the US .....	553
<i>Use of hESCs in NIH-supported research</i> .....	555
<i>Politics of hESC research in the US</i> .....	555
<i>Public opinion in the US about hESC research</i> .....	557
<i>Human stem cell cloning in the US</i> .....	559
<i>Stem cell guidelines of various US institutions</i> .....	559
Ethics of transplanting human NSCs into the brains of nonhuman primates .....	560
<b>ESC lines available worldwide</b> .....	<b>561</b>
<b>ESC policies around the world</b> .....	<b>562</b>

Countries with no defined policies on hESC research .....	562
Australia .....	562
Canada .....	563
China .....	564
Denmark .....	564
France .....	565
Germany .....	565
India .....	566
Ireland .....	567
Israel .....	568
Italy .....	568
Japan .....	568
Russia .....	569
The Netherlands .....	569
Saudi Arabia.....	570
Singapore .....	570
South Africa .....	570
South Korea .....	571
Spain .....	571
Sweden .....	572
Switzerland .....	572
United Kingdom .....	573
<i>UK StemCellBank</i> .....	573
European Union .....	574
<i>EU guidelines for stem cell research</i> .....	574
<i>European stem cell bank</i> .....	576
<i>EMBO's recommendations for stem cell research</i> .....	576
Public opinion in Europe about hESC research.....	577
United Nations, cloning and nuclear transfer.....	578
The Embryo Project for information on ESC research .....	578
Concluding remarks about ethics of ESC research .....	578
<b>Ethical issues concerning umbilical cord blood .....</b>	<b>579</b>
<b>Legal issues associated with stem cells .....</b>	<b>579</b>
Stem cell patents.....	579
<i>Stem cell patents in the United States</i> .....	579
<i>Current status of Thomson patents at WARF</i> .....	580
<i>Stem cell patents in the European Union</i> .....	581
<b>Cell therapy tourism .....</b>	<b>581</b>
<b>9. Safety and Regulatory Aspects of Cell Therapy .....</b>	<b>584</b>
<b>Introduction .....</b>	<b>584</b>
<b>Safety issues of cell therapy .....</b>	<b>584</b>
Immune-mediated reactions to transplanted stem cells .....	584
Human virus infections associated with stem cell transplantation .....	585
<i>Herpes simplex virus type 1</i> .....	585
<i>Cytomegalovirus</i> .....	585
Opportunistic infections among hematopoietic stem cell transplant recipients .....	585
Cord colitis syndrome .....	585
Carcinogenic potential of stem cells and its prevention .....	586
<b>Regulatory challenges for the clinical use of cell products.....</b>	<b>586</b>
Prediction of in vivo performance of cell-based therapies .....	587
<b>FDA safety regulations for cell and tissue products .....</b>	<b>587</b>
FDA Guidance on license applications for umbilical cord blood products.....	588
<b>Regulation of cord blood banks in the US .....</b>	<b>588</b>
<b>Regulatory issues for biotechnology-derived drugs .....</b>	<b>588</b>
<b>Regulation of products for adoptive cell therapy of cancer .....</b>	<b>589</b>
<b>Regulation of cell selection devices for PBSCs at point of care .....</b>	<b>589</b>
<b>FDA rules for human cells and tissues .....</b>	<b>590</b>
FDA regulation of fetal cellular or tissue products.....	591
<i>FDA and ESC lines</i> .....	591
FDA and clinical trials using hESCs .....	591
Cell and gene therapy INDs placed on hold by the FDA.....	592
Regulatory issues for genetically engineered cell transplants .....	593
FDA guidelines for human tissue transplantation .....	593
FDA considers cultured stem cells for therapy as drugs.....	593
FDA perspective on safety-efficacy and risk-benefit of stem cell therapy .....	593
FDA action against unapproved cell therapy in the US .....	594
<b>Xenotransplantation .....</b>	<b>595</b>
Clinical Protocol Review and Oversight.....	595
Informed consent and patient education .....	596
Xenotransplantation product sources .....	596

FDA guidelines for xenografts .....	597
US regulations for manufacture of cell therapy products .....	598
<i>GMP in USA</i> .....	599
<b>Regulations relevant to cell therapy in the European Union.....</b>	<b>599</b>
Regulations about use of stem cells in the EU .....	601
Guidelines for cell therapy in the UK.....	601
Quality requirements for ex vivo-expanded MSC products for clinical use .....	602
European regulations for manufacture of cell therapy products .....	602
<i>GMP in Europe</i> .....	603
<b>Global regulation of stem cell approval.....</b>	<b>603</b>
<b>Transport of stem cells between countries .....</b>	<b>603</b>
Temperature limitations during transport of stem cells .....	603
<b>NIH and stem cells.....</b>	<b>604</b>
hESC lines approved under the new NIH guidelines .....	604
<b>Clinical trials in cell therapy.....</b>	<b>604</b>
Assessment of clinical trial registration and publication .....	605
Misuse of listing on ClinicalTrials.gov to provide unapproved stem cell therapy .....	605

## Tables

Table 1-1: Landmarks in the history of cell therapy .....	31
Table 1-2: Examples of cells involved in various diseases .....	37
Table 2-1: Types of human cells used in cell therapy.....	41
Table 2-2: A selection of companies providing cell culture media .....	46
Table 2-3: A sampling of companies supplying cell sorters .....	52
Table 2-4: Companies involved in cell-based drug discovery .....	61
Table 2-5: Methods of delivery of cells for therapeutic purposes .....	64
Table 2-6: Therapeutic applications of encapsulated cells.....	69
Table 2-7: Companies working on encapsulated cell technology.....	71
Table 2-8: Molecular imaging methods for tracking cells in vivo.....	76
Table 3-1: Various levels of potency relevant to stem cells .....	84
Table 3-2: Clinical trials of UCB .....	112
Table 3-3: Companies involved in cord blood banking as a source of stem cells .....	115
Table 3-4: Comparison of techniques for nuclear reprogramming of stem cells .....	119
Table 3-5: Banks of patient-specific iPSC lines.....	124
Table 3-6: Companies providing iPSCs .....	125
Table 3-7: Sources of adult human stem cells .....	130
Table 3-8: Comparison of human stem cells according to derivation.....	142
Table 3-9: Enhancing engraftment, mobilization and expansion of stem cells .....	162
Table 3-10: Applications of stem cells .....	179
Table 3-11: Advantages and limitations of methods for optimizing MSCs .....	191
Table 3-12: Pharmaceutical manipulation of stem cells.....	198
Table 3-13: Growth factors with positive effects on stem cells and applications .....	199
Table 3-14: Examples of drugs that induce granulocytopenia at stem cell level.....	210
Table 3-15: Academic institutes involved in stem cell research .....	218
Table 3-16: Companies involved in stem cell technologies .....	220
Table 4-1: Therapeutic applications of regulatory T cells (Tregs).....	238
Table 4-2: Various tissue/cell therapy approaches to the treatment of type 1 diabetes .....	246
Table 4-3: Companies involved in cell therapy for insulin-dependent diabetes .....	263
Table 4-4: Major pulmonary disorders potentially treatable by stem cell manipulation .....	283
Table 4-5: Cell-based repair of knee cartilage damage .....	300
Table 4-6: Intraoperative cell therapy .....	333
Table 5-1: Classification of various types of cell therapy for cardiovascular disorders .....	338
Table 5-2: Clinical trials of cell therapy in cardiovascular disease .....	379
Table 6-1: Cell therapy technologies used for cancer .....	387
Table 6-2: Companies involved in developing cell-based therapies for cancer .....	428
Table 7-1: Studies in rats or mice of in vivo reprogramming of cells for brain repair.....	436
Table 7-2: NSCs-based approaches for neurological disorders. ....	450
Table 7-3: Experimental use of immortalized cells for CNS disorders .....	454
Table 7-4: Combination of stem cells and HBO in models of neurological disorders .....	459
Table 7-5: Therapeutic applications of MSCs for neurological disorders .....	461
Table 7-6: Methods for delivering cell therapies in CNS disorders.....	464
Table 7-7: Neurological disorders amenable to cell therapy .....	467
Table 7-8: Types of cell used for investigative treatment of Parkinson's disease .....	472
Table 7-9: Status of cell therapies for Parkinson's disease .....	473
Table 7-10: Role of cell therapy in management of stroke according to stage .....	501
Table 7-11: Clinical trials of cell therapy for stroke: completed, ongoing and pending .....	502
Table 7-12: Clinical trials of cell therapy for retinal degenerative disorders .....	544
Table 7-13: Clinical trials with cell therapy in neurological disorders (excluding stroke) .....	548
Table 8-1: Listed numbers of ESC lines around the world.....	561
Table 8-2: Stem cell policies around the world .....	562
Table 8-3: European public attitudes about research involving human stem cells .....	577

Table 9-1: Possible adverse reactions and safety issues of cell therapy.....	584
--	-----

## Figures

Figure 1-1: Interrelationships of cell therapy to other technologies .....	34
Figure 1-2: Interrelationships of gene, cell and protein therapies.....	35
Figure 1-3: Engineering of RBCs for drug delivery .....	39
Figure 3-1: A simplified biological scheme of embryonic stem Cells .....	84
Figure 3-2: Steps of iPS cell production .....	120
Figure 3-3: hESC-derived by somatic cell nuclear transfer .....	159
Figure 3-4: Flow chart of development of stem cells with potential bottlenecks.....	225
Figure 4-1: Reprogramming ESCs/iPSCs cells to $\beta$ -cells for type 1 diabetes .....	258
Figure 4-2: Fluorescently labeled polarized Upcyte® hepatocytes .....	266
Figure 5-1: Ex vivo vs in vivo approaches to regeneration of the heart .....	338
Figure 5-2: hESC-derived cardiomyocytes from laboratory to bedside .....	353
Figure 5-3: Steps in growing a new heart in vitro for transplantation.....	375
Figure 6-1: A scheme of generation and administration of tumor antigen-pulsed dendritic cells .....	397
Figure 6-2: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	400
Figure 6-3: Stem cell transplantation techniques .....	408
Figure 7-1: Cell-based methods for repair of the brain.....	433
Figure 7-2: Reprogramming methods for in vivo generation of neurons. ....	434
Figure 7-3: Stem cells that can give rise to neurons.....	444
Figure 7-4: Sources of dopaminergic neurons for transplantation in Parkinson’s disease .....	473
Figure 7-5: Scheme of iPSCs for personalized cell therapy of Parkinson disease.....	482
Figure 7-6: Potential mechanisms of stem cell efficacy in ALS .....	487
Figure 7-7: Approaches to stem cell therapy in stroke .....	497